C-Path’s Type 1 Diabetes Consortium (T1DC) is pleased to announce that “Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies” has been published in Diabetologia. The article reports on the work of the consortium and T1DC’s approach to obtaining regulatory endorsement of a model-based drug development tool.
